Telephone-Based Coaching Sessions (TAC) to Improve Advance Care Planning Participation in Advanced Cancer Patients and Their Support Person
Fred Hutchinson Cancer Center · NCT07141407
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 80
- US sites recruiting
- 3
- Study start
- April 8, 2026
- Record last updated
- August 25, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This clinical trial studies whether telephone-based coaching sessions, Talking About Cancer (TAC), work to improve engagement in advance care planning (ACP) in patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and their support person. Participation in ACP, which includes having end of life (EOL) care conversations and completing advance directives (e.g., living will, health care proxy, do not resuscitate order), improves quality EOL care. Despite this, less than half of patients with advanced cancer have EOL care conversations or complete advance directives. TAC coaching sessions are delivered by a social worker over the phone. They are designed to help patients and their support person communicate about ACP, manage the distress these conversations can cause, and participate in the process of ACP with a clear action plan of having goals-of-care conversations and completing advance directives. This may be an effective way to improve ACP participation in advanced cancer patients and their support person.
Being studied: Supportive Care; Telephone-Based Intervention; Survey Administration; Educational Intervention
Conditions: Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphatic System Neoplasm
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- PATIENT: Current diagnosis of stage III or IV cancer
- PATIENT: Able to provide informed consent
- PATIENT: Fluent in English or Spanish
- PATIENT: Have access to a telephone, computer, or mobile device
- CAREGIVER (SUPPORT PERSON): Person patient indicates provides support
- CAREGIVER (SUPPORT PERSON): English or Spanish speaking
- CAREGIVER (SUPPORT PERSON): 18 years of age or older
- CAREGIVER (SUPPORT PERSON): Able to provide informed consent
Exclusion Criteria
- PATIENT: Too ill or weak to complete the interviews (as judged by the interviewer)
- PATIENT: Receiving hospice at the time of enrollment
- PATIENT: Younger than age 18
Recruiting US locations
Providence Regional Cancer Partnership
Everett, WA 98201
Site contact: Megan Bannister, MSW, LSWAIC
Skagit Regional Health Cancer Care Center
Mount Vernon, WA 98274
Site contact: Kiarash Kojouri, MD
Fred Hutch/University of Washington Cancer Consortium
Seattle, WA 98109
Site contact: Megan Shen, PhD · 206-667-4172 · mshen2@fredhutch.org
Study contacts (from the official record)
- Megan Shen, PhD · 206-667-4172 · mshen2@fredhutch.org
Similar studies in Washington
All healthy volunteers studies in Washington →- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Seattle, WA + 49 other US sites
- Eligibility basics
- Ages 60+
- RecruitingHealthy volunteersPhase 1/Phase 2
A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older Adults
GlaxoSmithKline
- Location
- Seattle, WA + 2 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersPhase 1/Phase 2
A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age
GlaxoSmithKline
- Location
- Seattle, WA + 5 other US sites
- Eligibility basics
- Ages 18–64
- RecruitingHealthy volunteersPhase 1/Phase 2
Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)
Vega Therapeutics, Inc
- Location
- Seattle, WA + 9 other US sites
- Eligibility basics
- Ages 12–60